Gilead Sciences Inc (GILD) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Return on Equity, Quarterly Results, Trends, Rankings, Statistics
What is ROE for Gilead Sciences Inc in the second quarter 2026?
Gilead Sciences Inc had a negative return on equity (ROE) of -16.34%, due to the net loss of $-3 billion, during the twelve months ending in the second quarter 2026.
Within the Biotechnology & Pharmaceuticals industry 23 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 237, from total ROE ranking in the first quarter 2026 at 238.
Gilead Sciences, Inc. (Nasdaq: GILD), a leader in biopharmaceutical innovation, has announced promising data from the interim analysis of its ongoing Phase 3 ASSURE study. The data were revealed in a recent press release, highlighting significant developments in the management of primary biliary cholangitis (PBC) using Livdelzi (seladelpar), a drug that holds the potential to transform the treatment landscape for this chronic liver disease. Despite the company s financial curves, the medical advancements position Gilead at a poignant juncture in its healthcare journey. Livdelzi s Impressive Results in Treating Primary Biliary Cholangitis Primary biliary cholangitis, a progressive autoimmune disease, predominantly affects middle-aged women and can lead to liver cirrhosis or liver failure. Gilead s breakthrough drug, Livdelzi, has been in the spotlight due to its potential to alter the trajectory of this disease. In the two-and-a-half-year interim analysis from the Phase 3 ASSURE study, 81% of participants (30 out of 37) treated with Livdelzi achieved a composite biochemical response (CBR). This statistic underscores the drug’s efficacy in addressing key measures of PBC progression, a significant stride in patient care.
Unlocking New Horizons: Gilead’s Livdelzi Shines in PBC Treatment Amid Competitive Market Dynamics In the evolving landscape of hepatology, Gilead Sciences, Inc. (Nasdaq: GILD) continues to assert its presence, particularly regarding the management of primary biliary cholangitis (PBC) with its investigational drug, Livdelzi (seladelpar). Recent data from a two-and-a-half-year interim analysis of the ongoing Phase 3 ASSURE study illuminate the drug s promise, revealing that an impressive 81% of participants treated achieved a composite biochemical response (CBR). This robust finding not only underscores Livdelzi s potential in improving crucial indicators of PBC progression but also positions Gilead strategically within an increasingly competitive pharmaceutical landscape.Primary biliary cholangitis, an autoimmune disease affecting the liver, requires innovative and effective therapeutic solutions. The ASSURE study’s outcomes are particularly noteworthy: among the 37 participants evaluated, 41% achieved normalization in critical biomarkers associated with disease management. As PBC poses significant challenges for patients, and the market for effective treatments continues to grow, Gilead s findings could herald a new era in therapeutic options for this condition, offering hope to numerous patients worldwide.
In a significant stride towards HIV prevention and treatment, Gilead Sciences, Inc. has unveiled promising results from two pivotal clinical trials. Recently presented data from the Phase 3 PURPOSE 2 trial showcases the efficacy and safety of lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, in a diversified population of cisgender men and gender-diverse individuals. Meanwhile, the company also revealed positive interim results from the Phase 3 ASSURE study of Livdelzi (seladelpar), targeting primary biliary cholangitis (PBC). PURPOSE 2 Trial: Lenacapavir for HIV PreventionAt the recent HIV Glasgow conference, Gilead presented comprehensive findings from the PURPOSE 2 trial (NCT04925752), emphasizing lenacapavir s role as a preventive measure against HIV. The study gathered a diverse cohort, reaffirming Gilead s commitment to inclusivity in HIV research. Key data points such as adherence rates and pharmacokinetics of lenacapavir indicate that the treatment is not only effective but also manageable for patients. The twice-yearly administration offers a significant advantage in simplifying treatment regimens, potentially improving patient compliance, and addressing the needs of populations disproportionately affected by HIV. By targeting a wide demographic and focusing on a less frequent dosing schedule, lenacapavir could reshape the landscape of HIV prevention.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
